In yesterday’s Wall Street session, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) shares traded at $8.34, down -2.11% from the previous session.
3 analysts cover Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $9.00, we find $15.00. Given the previous closing price of $8.52, this indicates a potential upside of 76.06 percent. IRWD stock price is now -15.74% away from the 50-day moving average and -23.03% away from the 200-day moving average. The market capitalization of the company currently stands at $1.33B.
The stock has received a hold rating from 1 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $14.67 as their price target over the next twelve months.
With the price target of $15, CapitalOne recently initiated with Overweight rating for Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD).
In other news, John Minardo, Chief Legal Officer sold 7,045 shares of the company’s stock on Aug 14. The stock was sold for $70,732 at an average price of $10.04. Upon completion of the transaction, the Chief Legal Officer now directly owns 192,195 shares in the company, valued at $1.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 14, Principal Accounting Officer Silver Ronald sold 1,976 shares of the business’s stock. A total of $19,839 was realized by selling the stock at an average price of $10.04. This leaves the insider owning 134,172 shares of the company worth $1.12 million. Insiders disposed of 487,747 shares of company stock worth roughly $4.07 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IRWD stock. A new stake in Ironwood Pharmaceuticals Inc. shares was purchased by DRIEHAUS CAPITAL MANAGEMENT LLC during the first quarter worth $13,244,000. ADAGE CAPITAL PARTNERS GP, L.L.C. invested $7,871,000 in shares of IRWD during the first quarter. In the first quarter, SCHONFELD STRATEGIC ADVISORS LLC acquired a new stake in Ironwood Pharmaceuticals Inc. valued at approximately $1,845,000. ALPHACENTRIC ADVISORS LLC acquired a new stake in IRWD for approximately $1,314,000. ALPS ADVISORS INC purchased a new stake in IRWD valued at around $1,038,000 in the second quarter. In total, there are 361 active investors with 105.26% ownership of the company’s stock.
During the past 12 months, Ironwood Pharmaceuticals Inc. has had a low of $8.07 and a high of $12.66. The fifty day moving average price for IRWD is $9.86 and a two-hundred day moving average price translates $10.82 for the stock.
The latest earnings results from Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$6.71, missing analysts’ expectations of $0.25 by -6.96. This compares to $0.20 EPS in the same period last year. The company reported revenue of $107.38 million for the quarter, compared to $97.23 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.44 percent. For the current quarter, analysts expect IRWD to generate $113.35M in revenue.
Ironwood Pharmaceuticals Inc.(IRWD) Company Profile
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
